Theranostics: From molecular imaging using Ga-68 labeled tracers and PET/CT to personalized radionuclide therapy - the bad berka experience

Theranostics

Volumn 2, Issue 5, 2012, Pages 437-447

  Baum, Richard P ^a   Kulkarni, Harshad R ^a  

^a ZENTRALKLINIK BAD BERKA   (Germany)

Author keywords

Molecular imaging; Personalized radionuclide therapy; Theranostics

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID 1 OCTREOTIDE GALLIUM GA 68; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID DEXTRO PHENYLALANINE TYROSINE OCTREOTIDE GALLIUM GA 68; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID DEXTRO PHENYLALANINE TYROSINE THREONINE OCTREOTIDE GALLIUM GA 68; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID DEXTRO PHENYLALANINE TYROSINE THREONINE OCTREOTIDE LUTETIUM 177; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID DEXTRO PHENYLALANINE TYROSINE THREONINE OCTREOTIDE YTTRIUM Y 90; [[4 [[BIS (PHOSPHONOMETHYL)] CARBAMOYL]METHYL] 7,10 BIS(CARBOXYMETHYL) 1,4,7,10 TETRAAZACYCLODODEC 1 YL]ACETIC ACID GALLIUM GA 68; [[4 [[BIS (PHOSPHONOMETHYL)] CARBAMOYL]METHYL] 7,10 BIS(CARBOXYMETHYL) 1,4,7,10 TETRAAZACYCLODODEC 1 YL]ACETIC ACID LUTETIUM LU 177; ANTINEOPLASTIC AGENT; ARGINYLGLYCYLASPARTIC ACID; ARGINYLGLYCYLASPARTIC ACID LUTETIUM LU 177; DEMOBESIN GALLIUM 68; DEMOBESIN LUTETIUM LU 177; DEMOBESIN TC 99M; GALLIUM 68; GASTRIN GALLIUM GA 68; GLUCOSE GALLIUM 68; LUTETIUM 177; OCTREOTIDE; PENTETREOTIDE IN 111; PROTEIN KINASE INHIBITOR; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; SARABESIN 6 LUTETIUM LU 177; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; SOMATOSTATIN RECEPTOR 2; TRACER; TYROSINE GALLIUM GA 68; UNCLASSIFIED DRUG; UNINDEXED DRUG; YTTRIUM 90;

CANCER CHEMOTHERAPY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DOSIMETRY; DRUG HALF LIFE; DRUG MEGADOSE; HUMAN; LIVER METASTASIS; MOLECULAR IMAGING; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT SELECTION; PROTEIN EXPRESSION; RADIODIAGNOSIS; RADIOFREQUENCY ABLATION; REVIEW; SCINTIGRAPHY;

EID: 84864545273     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.3645     Document Type: Review

References (37)

1. Rösch F, Baum RP. Generator-based PET radiopharmaceuticals for molecular imaging of tumours: on the way to THERANOSTICS. Dalton Trans. 2011; 40: 6104-11.
2. Zhernosekov KP, Filosofov DV, Baum RP, et al. Processing of generator-produced 68Ga for medical application. J Nucl Med. 2007; 48: 1741-8.
3. Lamberts SWJ, Reubi JC, Krenning EP. Somatostatin and the con-cept of peptide receptor scintigraphy in oncology. Semin Oncol. 1994; 21: 1-5.
4. Krenning EP, Kwekkeboom DJ, de Jong M, et al. Essentials of pep-tide receptor scintigraphy with emphasis on somatostatin analog octreotide. Semin Oncol. 1994; 21: 6-14.
5. Hofmann M, Maecke H, Borner R, et al. Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data. Eur J Nucl Med Mol Imaging. 2001; 28: 1751-7.
6. Buchmann I, Henze M, Engelbrecht S, et al. Comparison of 68Ga-DOTATOC PET and 111In-DTPA-OC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imag-ing. 2007; 34: 1617-26.
7. Gabriel M, Decristoforo C, Kendler D, et al. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: com-parison with somatostatin receptor scintigraphy and CT. J Nucl Med. 2007; 48: 508-18.
8. Ambrosini V, Campana D, Bodei L, et al. 68Ga- DOTA-NOC PET/CT clinical impact in patients with neuroendocrine tumors. J Nucl Med. 2010; 51: 669-73.
9. Srirajaskanthan R, Kayani I, Quigley AM, et al. The role of 68Ga- DOTATATE PET in patients with neuroendocrine tumors and neg-ative or equivocal findings on 111In- DTPA-octreotide scintigraphy. J Nucl Med. 2010; 51: 875-82.
10. Boy C, Heusner TA, Poeppel TD, et al. (68)Ga-DOTATOC PET/CT and somatostatin receptor (sst1-sst5) expression in normal human tissue: correlation of sst2 mRNA and SUV(max). Eur J Nucl Med Mol Imaging. 2011; 38: 1224-36. 11.
11. 68Ga-SSTR PET/CT and correlation to immunohistochemistry of somatostatin receptors in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2011; 38: 1659-68.
12. Kowalski J, Henze M, Schuhmacher J, et al. Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-Octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol Imaging Biol. 2003; 5: 42-8.
13. Baum RP, Prasad V. PET and PET/CT Imaging of Neuroendocrine Tumors. In: Wahl R, ed. Principles and Practice of PET and PET/CT, 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2008: 411-37. 14.
14. Baum RP, Prasad V, Hommann M, et al. Receptor PET/CT imaging of neuroendocrine tumors. Recent Results in Cancer Research. 2007; 170: 225-42. 15.
15. Prasad V, Ambrosini V, Hommann M, et al. Detection of unknown primary neuroendocrine tumours (CUP-NET) using (68)Ga-DOTA-NOC receptor PET/CT. Eur J Nucl Med Mol Imag-ing. 2010; 37: 67-77. 16.
16. Prasad V, Baum RP. Biodistribution of the Ga-68 labeled somato-statin analogue DOTA-NOC in patients with neuroendocrine tu-mors: characterization of uptake in normal organs and tumor le-sions. Q J Nucl Med Mol Imaging. 2010; 54: 61-7.
17. Koukouraki S, Strauss LG, Georgoulias V, et al. Evaluation of the pharmacokinetics of (68)Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for (90)Y-DOTATOC therapy. Eur J Nucl Med Mol Imaging. 2006; 33: 460-6.
18. Naji M, Zhao C, Welsh SJ, et al. 68Ga-DOTA-TATE PET vs. 123I-MIBG in identifying malignant neural crest tumours. Mol Im-aging Biol. 2011; 13: 769-75.
19. Maecke HR, Hofmann M, Haberkorn U. (68)Ga-labeled peptides in tumor imaging. J Nucl Med. 2005; 46 (Suppl 1): S172- S178. 20.
20. Wehrmann C, Senftleben S, Zachert C, et al. Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTA-TATE and 177Lu DOTA-NOC. Cancer Biother Radi-opharm. 2007; 22: 406-16.
21. Prasad V, Hoersch D, Zachert C, et al. Five year follow-up of renal function in neuroendocrine tumor patients treated with 5 or more cycles of peptide receptor radionuclide therapy (PRRNT). J Nucl Med. 2011; 52 (Suppl 1): 299.
22. Prasad V, Kulkarni H, Zachert C, et al. Safety and efficacy of pep-tide receptor radionuclide therapy (PRRNT) in neuroendocrine tumor patients having single kidney or nonfunctional kidney. J Nucl Med. 2011; 52 (Suppl 1): 1741.
23. Kunikowska J, Królicki L, Hubalewska-Dydejczyk A, et al. Clini-cal results of radionuclide therapy of neuroendocrine tu-mours with90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a bettertherapy option? Eur J Nucl Med Mol Imaging. 2011; 38(10): 1788-97. 24.
24. Kaemmerer D, Prasad V, Daffner W, et al. Neoadjuvant peptide receptor radionuclide therapy for an inoperable neuroendocrine pancreatic tumor. World J Gastroenterol. 2009; 15: 5867-70. 25.
25. Sowa-Staszczak A, Pach D, Chrzan R, et al. Peptide receptor radi-onuclide therapy as a potential tool for neoadjuvant therapy in pa-tients with inoperable neuroendocrine tumours (NETs). Eur J Nucl Med Mol Imaging. 2011; 38: 1669-74.
26. Kwekkeboom DJ, de Herder WW, Kam BL, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008; 26: 2124-30.
27. Hörsch D, Grabowski P, Schneider CP, et al. Current treatment options for neuroendocrine tumors. Drugs Today. 2011; 47: 773-86. 28.
28. Pagou M, Zerizer I, Al-Nahhas A. Can gallium-68 compounds partly replace (18)F-FDG in PET molecular imaging? Hell J Nucl Med. 2009; 12: 102-5. 29.
29. Fellner M, Baum RP, Kubícek V, et al. PET/CT imaging of osteo-blastic bone metastases with (68)Ga-bisphosphonates: first human study. Eur J Nucl Med Mol Imaging. 2010; 37: 834. 30.
30. Schroeder RP, Müller C, Reneman S, et al. A standardised study to compare prostate cancer targeting efficacy of five radiolabelled bombesin analogs. Eur J Nucl Med Mol Imaging. 2010; 37: 1386-96.
31. Kotzerke J, Andreeff M, Wunderlich G, et al. Ventilation/Perfusion Scans Using Ga-68 Labeled Tracers. World J Nucl Med. 2011; 10: 26-59.
32. Froidevaux S, Calame-Christe M, Schuhmacher J, et al. A galli-um-labeled DOTA-alpha-melanocyte- stimulating hormone analog for PET imaging of melanoma metastases. J Nucl Med. 2004; 45(1): 116-23. 33.
33. Baum RP, Prasad V, Müller D, et al. Molecular imaging of HER2-expressing malignant tumors in breast cancer patients us-ing synthetic 111In- or 68Ga-labeled affibody molecules. J Nucl Med. 2010; 51: 892-7.
34. Baum RP, Kulkarni HR, Schuchardt C, et al. First Clinical Experi-ence using 177Lu-BPAMD for the Treatment of Skeletal Metastases in Prostate Cancer. Eur J Nucl Med Mol Imaging. 2011; 38 (Suppl 2): S225.
35. 77Lu-labeled RGD derivative for targeting angiogenesis. Cancer Biother Radiopharm. 2010; 25(6): 687-91.
36. Majkowska-Pilip A, Bilewicz A. Macrocyclic complexes of scandi-um radionuclides as precursors for diagnostic and therapeutic ra-diopharmaceuticals. J Inorg Biochem. 2011; 105(2): 313-20.
37. Pruszyński M, Loktionova NS, Filosofov DV, et al. Post-elution processing of (44)Ti/ (44)Sc generator-derived (44)Sc for clinical application. Appl Radiat Isot. 2010; 68(9): 1636-41.